Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Synlogic (DE:MIN)
BERLIN:MIN
Holding DE:MIN?
Track your performance easily
MIN Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.26 - €1.90
Previous Close€1.45
Volume0.00
Average Volume (3M)N/A
Market Cap
€15.60M
Enterprise Value-€3.15M
Total Cash (Recent Filing)$19.97M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Mar 13, 2025EPS Estimate
-€0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,696,109
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.07
Price to Sales (P/S)5.34
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.99
Enterprise Value/Gross Profit-0.94
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Synlogic News
PremiumCompany Announcements
Synlogic Appoints James Flynn to Board Amidst Director Resignations
Bulls Say, Bears Say
Bulls Say
Capital ManagementSYBX's prudent capital management is evident from its impressive cash reserves and zero net debt.
Financial PerformanceSYBX boasts a strong financial position with zero net debt to total capital.
LiquiditySYBX maintains a solid liquidity profile with $20M in cash, cash equivalents, and short-term marketable securities.
Bears Say
Program DiscontinuationSYBX announced a surprising decision to discontinue their lead program, SYNB1934 in phenylketonuria (PKU).
Strategic EvaluationThere are low expectations that SYBX's programs will be acquired for further development.
Study ResultsThe company saw no trends in Phe lowering from their open-label portion of the study.
---
Options Prices
Currently, No data available
---
Ownership Overview
17.92% Insiders
3.32% Mutual Funds
<0.01% Other Institutional Investors
77.21% Public Companies and
Individual Investors
MIN FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was €0.26 and its highest was €1.90 in the past 12 months.
What is Synlogic’s market cap?
Currently, no data Available
When is Synlogic’s upcoming earnings report date?
Synlogic’s upcoming earnings report date is Mar 13, 2025 which is in 120 days.
How were Synlogic’s earnings last quarter?
Synlogic released its earnings results on Nov 07, 2024. The company reported -€0.009 earnings per share for the quarter, beating the consensus estimate of -€0.169 by €0.16.
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate is -€0.09.
How many shares outstanding does Synlogic have?
Synlogic has 11,696,109 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Synlogic reported an EPS of -€0.009 in its last earnings report, beating expectations of -€0.169. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Synlogic?
Among the largest hedge funds holding Synlogic’s share is RA Capital Management. It holds Synlogic’s shares valued at N/A.
---
Synlogic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
DE:MIN Sentiment 100%
Sector Average 73%
Sector Average 73%
Insider Transactions
Sold Shares
Worth $110.6 over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.24%
12-Months-Change
Fundamentals
Return on Equity
-158.75%
Trailing 12-Months
Asset Growth
-72.71%
Trailing 12-Months
Company Description
Synlogic
Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.
---
MIN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Synlogic
―
ADMA Biologics
―
Agenus
―
Adaptimmune Therapeutics
―
Aclaris Therapeutics
―
Best Analysts Covering MIN
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-53.40%
initiated a buy rating 11 months ago
Copying James Molloy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -53.40% per trade.
---